Clinical Trials Logo

Androgenetic Alopecia clinical trials

View clinical trials related to Androgenetic Alopecia.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06149221 Completed - Clinical trials for Androgenetic Alopecia

Penetration-enhanced Direct DBD Non-thermal Plasma for Hair Loss

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

In-office applied non-thermal atmospheric pressure plasma treatment on NS pretreated scalp

NCT ID: NCT05989165 Completed - Clinical trials for Androgenetic Alopecia

Effectiveness of Combination Therapy of Microneedling and Minoxidil in Androgenetic Alopecia of Indonesian Men

Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare the effectiveness of combination therapy of microneedling and minoxidil in androgenetic alopecia of Indonesian men. The main questions it aims to answer are: - Is there an increase in hair density with combination therapy of microneedling and minoxidil versus minoxidil monotherapy? - Is there an increase in hair diameter with combination therapy of microneedling and minoxidil versus minoxidil monotherapy? Participants will be divided into 2 groups. The first one will receive minoxidil monotherapy, and the second one will receive a combination therapy of microneedling and minoxidil. Researchers will compare those 2 groups to see if there is a difference of effectiveness based on hair density and diameter.

NCT ID: NCT05636904 Completed - Clinical trials for Androgenetic Alopecia

Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

Start date: December 5, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to measure the safety, tolerability, and the hair growth response to topical DLQ01 solutions in comparison to the vehicle and a comparator solution in 120 males with Androgenetic Alopecia.

NCT ID: NCT05428449 Completed - Acne Vulgaris Clinical Trials

Study in Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029

Start date: February 10, 2022
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled, parallel group, dose escalation study to evaluate the safety, tolerability and pharmacokinetics (PK) of GT20029 following topical single ascending dose in healthy subjects and multiple ascending dose administration in subjects with androgenetic alopecia(AGA) or acne

NCT ID: NCT05324293 Completed - Clinical trials for Androgenetic Alopecia

To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period

Start date: May 11, 2022
Phase: Phase 1
Study type: Interventional

An Open Label Study, to Evaluate Safety, Tolerability, and Efficacy Study in Male and Female with Androgenetic Alopecia Treated with HMI-115 over a 24-Week Treatment Period.

NCT ID: NCT04984707 Completed - Clinical trials for Androgenetic Alopecia

Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Start date: January 28, 2019
Phase: Phase 1
Study type: Interventional

The study is a Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Male Subjects with Androgenetic Alopecia to Evaluate the Safety, Tolerability and Pharmacokinetics of KX-826 Following Topical Single Ascending Dose Administration

NCT ID: NCT04945226 Completed - Clinical trials for Androgenetic Alopecia

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

Start date: September 21, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001

NCT ID: NCT04898166 Completed - Covid19 Clinical Trials

Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).

Start date: December 1, 2020
Phase:
Study type: Observational [Patient Registry]

Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.

NCT ID: NCT04825561 Completed - Clinical trials for Androgenetic Alopecia

A Study to Evaluate the Efficacy and Safety of AD-208

Start date: June 9, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AD-208.

NCT ID: NCT04774874 Completed - Clinical trials for Androgenetic Alopecia

A Phase 2a Trial of FOL-005 Topical Formulations to Investigate Hair Growth Potential and Safety in Healthy Male Volunteers

Start date: June 24, 2020
Phase: Phase 2
Study type: Interventional

This exploratory phase IIa, double blind, randomized, vehicle controlled, multicenter dose-finding trial will evaluate the safety, tolerability, and efficacy of FOL-005 topical formulation (at 0.1%, 0.5% and 1.5% strength) administered once daily (in the evening) for 16 weeks in healthy male subjects with androgenetic alopecia.